Comparing Viridian Therapeutics (NASDAQ:VRDN) & AnPac Bio-Medical Science (NASDAQ:ANPC)

Viridian Therapeutics (NASDAQ:VRDNGet Rating) and AnPac Bio-Medical Science (NASDAQ:ANPCGet Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, institutional ownership and valuation.


This table compares Viridian Therapeutics and AnPac Bio-Medical Science’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Viridian Therapeutics -2,680.16% N/A -47.70%
AnPac Bio-Medical Science N/A N/A N/A

Valuation & Earnings

This table compares Viridian Therapeutics and AnPac Bio-Medical Science’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Viridian Therapeutics $2.96 million 120.46 -$79.41 million ($7.69) -1.79
AnPac Bio-Medical Science $3.14 million 1.81 -$12.33 million N/A N/A

AnPac Bio-Medical Science has higher revenue and earnings than Viridian Therapeutics.

Institutional and Insider Ownership

1.3% of AnPac Bio-Medical Science shares are held by institutional investors. 8.7% of Viridian Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Viridian Therapeutics has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500. Comparatively, AnPac Bio-Medical Science has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Viridian Therapeutics and AnPac Bio-Medical Science, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viridian Therapeutics 0 0 5 0 3.00
AnPac Bio-Medical Science 0 0 0 0 N/A

Viridian Therapeutics presently has a consensus target price of $34.75, suggesting a potential upside of 152.54%. Given Viridian Therapeutics’ higher possible upside, research analysts plainly believe Viridian Therapeutics is more favorable than AnPac Bio-Medical Science.


AnPac Bio-Medical Science beats Viridian Therapeutics on 6 of the 10 factors compared between the two stocks.

Viridian Therapeutics Company Profile (Get Rating)

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.

AnPac Bio-Medical Science Company Profile (Get Rating)

AnPac Bio-Medical Science Co., Ltd., a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests to corporations and life insurance companies in the People's Republic of China. It offers cancer differentiation analysis devices and physical checkup package services. The company was incorporated in 2010 and is headquartered in Lishui, the People's Republic of China.

Receive News & Ratings for Viridian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viridian Therapeutics and related companies with's FREE daily email newsletter.